Chantix Side Effects Stem From Flawed Clinical Testing

Chantix is now well known to cause serious psychological side effects in patients, including increased rates of depression, rage, and suicidal thoughts. It was introduced to the United States pharmaceuticals market in 2006 after early clinical trials showed high effectiveness and a low rate of side effects. However, soon after its introduction, patients began complaining of the severe Chantix side effects is now known for.





Chantix works, unlike other smoking cessation aids, without the help of nicotine. It blocks nicotine from binding to receptors in the brain, eliminating some of the pleasurable aspects of smoking, and decreases some effects of nicotine withdrawal by stimulating dopamine receptors, which mimics the effects of nicotine to an extent. All of this seemed promising to many consumers, and gave hope to the millions of smokers across the country looking for a way to quit.

However, serious issues with the product quickly became clear. Chantix blackouts and mood swings have been reported along with other psychological issues. Chantix lawsuits are based on consequences of these side effects, and many plaintiffs are claiming that Chantix did not conduct their clinical trials in an appropriate manner. They did not represent individuals with a history of mental disorders in their clinical trials – despite the fact that almost half of all cigarettes sold in America are purchased by people with some form of mental disorder.

This exclusion was a glaring oversight in clinical testing on the part of Pfizer, the manufacturer of Chantix. Because of the mistake the drug company has made, many Chantix patients are looking into filing Chantix lawsuits due to their psychological side effects. These lawsuits will be combined in multidistrict litigation, meaning pretrial procedures will be combined to make the entire legal process more efficient.

Common points in Chantix lawsuits include the statement that Pfizer was negligent in performing their clinical trials and as such misrepresented the potential risks to potential patients.